- Features of included articles (N=14) (continuation).
| Author name and year | Age | Number of lesions | Modality and optimal cutoff | The amino acid tracers of PET | PET modality | Follow-up period (month) | Reference standard |
|---|---|---|---|---|---|---|---|
| Cicone et al28 2015 | 38–84 | 46 (PET) 37 (PWI) | *SUVLmax/Bkgrmax (rSUV), 1.59 *rCBV, 2.14 | F-DOPA | PET/CT | 6 | Histopathology+clinico-radiological follow-up |
| Dandois et al29 2010 | 25-74 | 33 | *rCBV, 182% *rCBV, 378% | 11C-methionine | PET | 3 to 40 | Histopathology |
| D’Souza et al30 2014 | 15-61 | 29 | *SUV, ND *rCBV, 182% | 11C-methionine | PET/CT | 6 to 28 | Histopathology+clinico-radiological follow-up |
| Estrada et al31 2008 | 17-77 | 30 | *SUV, ND *rCBV, 1.2 | 18F-FDG | PET/MRI | 6 to 21 | Clinical and radiological criteria |
| Hatzoglou et al322016 | 19–81 | 55 | *SUVratio, 1.2 *Vpratio, 2.1 | 18F-FDG | PET/CT | 6 | Histopathology+clinico-radiological follow-up |
| Hojjati et al33 2018 | 34-81 | 28 (PET/MRI) 27 (PWI) 23 (PET/CT) | *r-Mean, 1.47 *CBVmax, 3.32 | 18F-FDG | PET/CT | 8 to 18 | Histopathology+clinico-radiological follow-up |
| Jabeen et al34 2021 | 8-71 | 48 | *TBRmax, 1.23 *rCBVratio, 1.38 | 11C-methionine | PET/MRI | 1 to 14 | Histopathology+clinico-radiological follow-up |
| Kim et al35 2010 | 31-66 | 10 | *Lmax/Rmax, 2.64 *rCBV, 3.69 | 11C-methionine + 18F-FDG | PET | 6 to 50 | Histopathology+clinical course |
| Prat et al36 2010 | 18-70 | 26 | ND | 18F-FDG | PET | 5 | Histopathology+clinico-radiological follow-up |
| Pyka et al37 2018 | 42-64 | 63 | *TBR, 2.07 *rCBV, 3.35 | 18F-FET | PET/MRI | 6 | Histopathology+ imaging follow-up |
| Qiao et al38 2019 | ND | 42 | *TBRSUVmax, 1.85 *rCBVmean, 1.83 | 11C-methionine | PET/CT | 6 | Histopathology+ Clinical follow up |
| Sacconi et al39 2016 | 14–74 | 34 | *SUVmean, <4.0 *rCBVmean, <1.74 | 18F-FDG | PET/MRI | 3 to 6 | Histopathology |
| Seligman et al40 2019 | 21-79 | 41 | *Whole-tumor SUVmean divided by SUVmean of normal white matter >0.75 *Mean Ktrans of whole tumor divided by mean Ktrans of contralateral brain >4.5 | 18F-FDG | PET/MRI | 6 | Histopathology+clinico-radiological follow-up |
| Steidl et al41 2021 | 20–78 | 104 | *Slope, <0.69 *rCBVmax, >2.85 | 18F-FET | PET/MRI | 6 | Histopathology+clinico-radiological follow-up |
ND - not defined, PET - positron emission tomography, MRI - magnetic resonance imaging, CT - computed tomography, PWI - perfusion-weighted imaging, 18F-FDG - 18fluorine-fluorodeoxyglucose, 18F-FET - 18F-fluoro-ethyl-tyrosine, 18F-FLT- (18)Fluorothymidine, CBV - Cerebral Blood Volume, TBR - Tumor to Background Ratio SUV - Standardized Uptake Value, F-DOPA - fluorodopa